Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group.
We report on the distress associated with physical symptoms in 761 male hypertensive patients enrolled in a clinical trial of the effects of captopril, methyldopa or propranolol on quality of life. Educational level at entry into the trial showed a negative association with a series of physical symptom distress items among patients not previously treated with antihypertensive medications but no association with symptoms among the previously treated. Over the 24 weeks of therapy captopril as monotherapy was associated with no change from baseline in distress in all symptoms examined. In contrast, distress increased in the methyldopa treated patients for dry mouth and blurred vision. Propranolol treated patients had increased "trouble getting breath," bradycardia, shortness of breath or wheezing, and blurred vision. Between group comparisons revealed significant differences favorably comparing captopril to both methyldopa and propranolol in regard to fatigue, and blurred vision, as well as to methyldopa alone for dry mouth and "feeling worn out." There were significant differences as well between captopril and propranolol with patients on propranolol worsening in bradycardia. Other comparisons of patients on propranolol and methyldopa monotherapy showed propranolol patients worsening in bradycardia and loss of taste, but methyldopa patients reported more dry mouth and feeling worn out than those on propranolol. The addition of hydrochlorothiazide to therapy worsened total physical symptom distress scores for methyldopa and propranolol patients. This study confirms the value of methods which assess the degree of distress associated with symptoms commonly reported by hypertensive patients receiving antihypertensive medications. This approach can be useful in establishing a treatment regimen least likely to cause distress and can be of value in preserving quality of life, preventing noncompliance, and withdrawal from treatment.
Schoenberger
J A
JA
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
Croog
S H
SH
Sudilovsky
A
A
Levine
S
S
Baume
R M
RM
D000328:Adult; D000367:Age Factors; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004522:Educational Status; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000009:adverse effects; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D011897:Random Allocation; D014481:United States
D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D008750:Methyldopa; D002216:Captopril; D011433:Propranolol